CDW Holding: Next-Generation LNP Delivery Technology LNP-LANFA Delivers Groundbreaking Preclinical Results

NewTimeSpace News: On June 29, 2026, CDW Holding announced that LNP-LANFA jointly developed by its subsidiary A Biotech and Neoregen Biotech has generated breakthrough data in animal experiments. LNP-LANFA incorporates the company’s proprietary water-soluble LANFA compounds into the LNP delivery system, designed to tackle two core challenges of conventional LNP technology: immunogenicity and hepatotoxicity.

Per the announcement, in vivo imaging (IVIS) test results show that versus conventional LNPs, LNP-LANFA cuts liver accumulation by 62% and raises drug concentration in the spleen by 28%. The spleen-to-liver ratio is lifted from 0.79 to 2.68, representing a 3.4-fold improvement. The company filed a provisional patent application covering LANFA-modified LNP formulations in June 2026.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.